A guide to COVID-19 antiviral therapeutics : a summary and perspective of the antiviral weapons against SARS-CoV-2 infection
© 2022 Federation of European Biochemical Societies..
Antiviral therapies are integral in the fight against SARS-CoV-2 (i.e. severe acute respiratory syndrome coronavirus 2), the causative agent of COVID-19. Antiviral therapeutics can be divided into categories based on how they combat the virus, including viral entry into the host cell, viral replication, protein trafficking, post-translational processing, and immune response regulation. Drugs that target how the virus enters the cell include: Evusheld, REGEN-COV, bamlanivimab and etesevimab, bebtelovimab, sotrovimab, Arbidol, nitazoxanide, and chloroquine. Drugs that prevent the virus from replicating include: Paxlovid, remdesivir, molnupiravir, favipiravir, ribavirin, and Kaletra. Drugs that interfere with protein trafficking and post-translational processing include nitazoxanide and ivermectin. Lastly, drugs that target immune response regulation include interferons and the use of anti-inflammatory drugs such as dexamethasone. Antiviral therapies offer an alternative solution for those unable or unwilling to be vaccinated and are a vital weapon in the battle against the global pandemic. Learning more about these therapies helps raise awareness in the general population about the options available to them with respect to aiding in the reduction of the severity of COVID-19 infection. In this 'A Guide To' article, we provide an in-depth insight into the development of antiviral therapeutics against SARS-CoV-2 and their ability to help fight COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:291 |
|---|---|
| Enthalten in: |
The FEBS journal - 291(2024), 8 vom: 24. Apr., Seite 1632-1662 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brady, Drugan K [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.04.2024 Date Revised 18.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/febs.16662 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347808875 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347808875 | ||
| 003 | DE-627 | ||
| 005 | 20240418232147.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/febs.16662 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1379.xml |
| 035 | |a (DE-627)NLM347808875 | ||
| 035 | |a (NLM)36266238 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brady, Drugan K |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A guide to COVID-19 antiviral therapeutics |b a summary and perspective of the antiviral weapons against SARS-CoV-2 infection |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.04.2024 | ||
| 500 | |a Date Revised 18.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Federation of European Biochemical Societies. | ||
| 520 | |a Antiviral therapies are integral in the fight against SARS-CoV-2 (i.e. severe acute respiratory syndrome coronavirus 2), the causative agent of COVID-19. Antiviral therapeutics can be divided into categories based on how they combat the virus, including viral entry into the host cell, viral replication, protein trafficking, post-translational processing, and immune response regulation. Drugs that target how the virus enters the cell include: Evusheld, REGEN-COV, bamlanivimab and etesevimab, bebtelovimab, sotrovimab, Arbidol, nitazoxanide, and chloroquine. Drugs that prevent the virus from replicating include: Paxlovid, remdesivir, molnupiravir, favipiravir, ribavirin, and Kaletra. Drugs that interfere with protein trafficking and post-translational processing include nitazoxanide and ivermectin. Lastly, drugs that target immune response regulation include interferons and the use of anti-inflammatory drugs such as dexamethasone. Antiviral therapies offer an alternative solution for those unable or unwilling to be vaccinated and are a vital weapon in the battle against the global pandemic. Learning more about these therapies helps raise awareness in the general population about the options available to them with respect to aiding in the reduction of the severity of COVID-19 infection. In this 'A Guide To' article, we provide an in-depth insight into the development of antiviral therapeutics against SARS-CoV-2 and their ability to help fight COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Arbidol | |
| 650 | 4 | |a COVID‐19 | |
| 650 | 4 | |a Evusheld | |
| 650 | 4 | |a Kaletra | |
| 650 | 4 | |a Paxlovid | |
| 650 | 4 | |a REGEN‐COV | |
| 650 | 4 | |a SARS‐CoV‐2 | |
| 650 | 4 | |a antiviral | |
| 650 | 4 | |a bamlanivimab and etesevimab | |
| 650 | 4 | |a bebtelovimab | |
| 650 | 4 | |a chloroquine | |
| 650 | 4 | |a dexamethasone | |
| 650 | 4 | |a favipiravir | |
| 650 | 4 | |a interferons | |
| 650 | 4 | |a ivermectin | |
| 650 | 4 | |a molnupiravir | |
| 650 | 4 | |a nitazoxanide | |
| 650 | 4 | |a remdesivir | |
| 650 | 4 | |a ribavirin | |
| 650 | 4 | |a sotrovimab | |
| 650 | 4 | |a therapeutics | |
| 650 | 4 | |a treatment | |
| 650 | 4 | |a virus | |
| 650 | 7 | |a nitazoxanide |2 NLM | |
| 650 | 7 | |a SOA12P041N |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Nitro Compounds |2 NLM | |
| 650 | 7 | |a Thiazoles |2 NLM | |
| 700 | 1 | |a Gurijala, Aashi R |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Liyu |e verfasserin |4 aut | |
| 700 | 1 | |a Hussain, Ali A |e verfasserin |4 aut | |
| 700 | 1 | |a Lingan, Audrey L |e verfasserin |4 aut | |
| 700 | 1 | |a Pembridge, Olivia G |e verfasserin |4 aut | |
| 700 | 1 | |a Ratangee, Brina A |e verfasserin |4 aut | |
| 700 | 1 | |a Sealy, Tristan T |e verfasserin |4 aut | |
| 700 | 1 | |a Vallone, Kyle T |e verfasserin |4 aut | |
| 700 | 1 | |a Clements, Thomas P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The FEBS journal |d 2005 |g 291(2024), 8 vom: 24. Apr., Seite 1632-1662 |w (DE-627)NLM15295631X |x 1742-4658 |7 nnns |
| 773 | 1 | 8 | |g volume:291 |g year:2024 |g number:8 |g day:24 |g month:04 |g pages:1632-1662 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/febs.16662 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 291 |j 2024 |e 8 |b 24 |c 04 |h 1632-1662 | ||